Digital Therapeutics (DTx) are software-driven treatments designed to prevent, manage, or treat medical conditions using clinically validated interventions, and in many cases, FDA-cleared prescription digital therapeutics. In 2026, they are no longer experimental pilots; they are structured, regulated tools embedded into real care pathways and benefit designs.
This article examines 10 digital therapeutics platforms reshaping patient care in 2026 by focusing on regulatory status, measurable outcomes, payer adoption, and real-world operational fit. You will see where regulated prescription digital therapeutics lead, where enterprise-scale ROI drives buying decisions, and how to evaluate platforms across MSK, cardiometabolic health, mental health, sleep, IBS, respiratory care, ADHD, and substance use treatment.
1. Hinge Health (Musculoskeletal Pain And Digital Physical Therapy)
If musculoskeletal care sits anywhere near the top of your claims stack, Hinge Health tends to show up early in the vendor shortlist. The offering is positioned as a digital MSK program that blends guided exercise therapy, education, and care team support, with optional hardware that supports engagement and symptom relief. The practical reason it keeps winning deals is operational: it fits benefit designs, onboarding flows, and reporting expectations that employers and payers already understand.
In 2026 buying cycles, MSK platforms get judged on more than engagement rates. You’re expected to produce credible utilization impact, measurable improvements in pain and function, and clean reporting that benefits leaders can defend. Hinge Health markets ROI-oriented analyses, including a Medicare-focused ROI claim and separate employer ROI claims, and it reinforces its position with recurring “state of MSK” style reporting that aligns with how plan sponsors make renewal decisions. That said, it’s still on you to validate methodology details, attribution rules, and what populations were included before treating ROI as forecastable.
Patient trust issues matter here more than many executives admit. Community posts describe frustrations around billing clarity, perceived “device lock-in,” and what happens when eligibility ends. When a member believes enrollment is “free” and later sees claims activity, the care experience turns into a finance dispute, and outcomes stop mattering. If Hinge Health is under evaluation, insist on member-facing disclosures that explain when billing can begin, what triggers a claim, and how offboarding works when coverage changes.
2. Omada Health (Diabetes, Hypertension, Weight, GLP-1 Companion Support)
Omada Health has built durable enterprise demand by staying anchored to cardiometabolic care, where the outcomes are numeric, frequent, and expensive when unmanaged. The platform typically blends behavior change programming, coaching, education, and data capture, all designed to influence A1C, blood pressure, weight, and medication adherence. The buyer appeal is that cardiometabolic programs can be evaluated in a finance meeting without translating symptom scales into dollars.
Omada’s messaging leans heavily on published outcomes and longitudinal results. A widely circulated example highlights A1C reduction and sustained weight maintenance for members in its type 2 diabetes program, using a commercially insured cohort with repeated measures across the first year. For decision-makers, the useful takeaway is not the marketing headline, it’s that Omada routinely plays the “show your work” game that procurement teams demand: population definition, baseline segmentation, and time-based reporting rather than one-time snapshots.
In 2026, the conversation quickly moves toward GLP-1 stewardship and medication-adjacent digital care. Employers and plans want proof that a digital layer improves persistence, reduces rebound risk after discontinuation, and supports sustainable behavior change without creating member fatigue. You should treat every vendor’s “GLP-1 optimization” claim as a contracting topic: define what counts as adherence support, how outcomes get attributed, which behaviors are tracked, and how the program avoids turning into endless logging that members abandon.
3. Big Health DaylightRx (Prescription Digital CBT For Generalized Anxiety Disorder)
DaylightRx matters because it sits on the regulated side of digital mental health, where a product is evaluated as a medical device rather than a general wellness app. It’s positioned as a prescription digital therapeutic delivering cognitive behavioral therapy for generalized anxiety disorder, intended to improve symptoms as an adjunct to usual care in adults. That framing changes procurement, clinical governance, and the expectation for labeling clarity and evidence.
From an implementation standpoint, prescription status forces you to think about workflow: who prescribes, how eligibility is determined, how onboarding happens, and where follow-up lives. If you deploy DaylightRx into a system without mapping it into clinical operations, usage drops and the prescribing base stops writing new starts. When the workflow is clean, regulated products can create a consistent standard for non-drug therapy access, which is often the real gap in anxiety care.
When evaluating DaylightRx, focus on three operational questions. How is engagement sustained over the treatment duration, what outcomes are measured in a way clinicians accept, and how does the vendor support provider adoption without creating inbox burden. Digital CBT programs fail less from clinical content and more from real-life friction: sign-up steps, prescription logistics, and weak handoffs between the app experience and clinician-managed care.
4. Nox Health Somryst (Prescription Digital CBT-I For Chronic Insomnia)
Somryst remains a highly referenced name in digital insomnia treatment because it has been described as an FDA-cleared prescription digital therapeutic for chronic insomnia delivering CBT-I. Nox Health’s acquisition kept Somryst alive after Pear Therapeutics’ restructuring, which matters to buyers who care about product continuity, support, and long-term contracting stability. Sleep is also a gateway condition in population health, improving insomnia can affect downstream cardiometabolic and mental health risk.
CBT-I is clinically respected, and that credibility carries into digital delivery when the program adheres to established treatment components. In practice, insomnia programs win when they balance clinical fidelity with usability. If the product feels like homework, drop-off rises. If the program dilutes CBT-I to protect engagement, outcomes weaken. You’re looking for the middle: a program that preserves CBT-I structure while keeping the member experience realistic for people who are already exhausted.
When Somryst is under consideration, pay attention to how it fits into existing sleep pathways. Many systems already manage sleep apnea referrals, diagnostic testing, and PAP adherence. Insomnia treatment often lacks similar operational rigor. A digital CBT-I option can fill that gap if you define who gets offered the tool, how comorbidities are handled, and how escalation to clinicians occurs when red flags show up.
5. Click Therapeutics And Otsuka Rejoyn (Prescription Digital Therapeutic For MDD Symptoms, Adjunctive Use)
Rejoyn is one of the clearest examples of regulated mental health DTx moving into mainstream awareness. Otsuka and Click Therapeutics announced FDA clearance for Rejoyn as a prescription digital therapeutic authorized for major depressive disorder symptom treatment as an adjunct to clinician-managed outpatient care in adults aged 22 and older. That “adjunct” label is not fine print; it affects positioning, patient selection, and how success gets measured.
From a commercial lens, depression is a high-need, high-volume condition with uneven access to psychotherapy and variable medication response. Digital adjuncts can add structure between visits, creating more consistent practice of cognitive and emotional skills. Your deployment success will track with how well Rejoyn is introduced. If the prescribing clinician frames it as “another app,” you’ll get app-like retention. If it’s framed as a structured course of treatment with a defined duration, engagement and outcomes tend to behave more like a program.
To evaluate Rejoyn with discipline, ask what the system will do with results. Will symptom scale changes feed back to clinicians, care managers, or behavioral health navigators. Can the tool support measurement-based care without adding manual work. A prescription digital therapeutic is easiest to justify when it tightens clinical operations, not when it adds a parallel experience no one monitors.
6. Better Therapeutics AspyreRx (Prescription Digital Therapeutic For Type 2 Diabetes)
Better Therapeutics is tied to AspyreRx, a prescription digital therapeutic authorized for type 2 diabetes behavior change support. The product narrative centers on delivering CBT-based interventions that influence glycemic control through behavior and habit change, rather than only education. The strategic appeal is obvious: diabetes costs are large, and behavior-driven risk factors are persistent.
In evaluation, you should separate two questions that often get mixed. First, does the product improve clinical markers in the populations you cover, with the comorbidity patterns you see, and with the adherence reality you already know. Second, does the program fit your reimbursement and access model. Prescription products can be powerful clinically but still struggle when prescribing workflows and payer coverage are not aligned. Operational fit often decides scale more than clinical merit.
Better Therapeutics has also communicated additional regulatory momentum through Breakthrough Device Designation tied to advanced liver disease areas related to metabolic dysfunction. That matters for a 2026 planning cycle because comorbidity clustering is the rule, not the exception. If you’re investing in cardiometabolic digital care, you want vendors whose roadmaps match the real member profile: diabetes plus obesity plus liver risk plus hypertension, not siloed condition programs that create five logins.
7. Mahana Therapeutics Parallel And Mahana IBS (Prescription Digital Therapeutic For IBS)
IBS is one of the best demonstrations that digital therapeutics can address conditions where standard care often leaves patients cycling through visits, diets, and tests. Mahana Therapeutics’ Parallel and Mahana IBS products are positioned as prescription digital therapeutics using CBT-based approaches to reduce symptom burden. FDA De Novo authorization for the web version and later clearance for a mobile version built a regulatory foundation that distinguishes it from general IBS coaching apps.
IBS programs succeed when they get patient selection right and set expectations well. Members who expect instant relief typically disengage. Members who understand that symptom reduction comes through structured skill-building and consistent practice are more likely to complete the course. Your job in deployment is to build that expectation into the referral and onboarding process, so the DTx doesn’t get blamed for mismatch between promised speed and realistic timelines.
For payers and health systems, the operational win is reduced churn across specialists and repeated diagnostics when a clear IBS diagnosis already exists. The DTx should sit inside a defined pathway: rule-out steps, diagnosis confirmation, prescription, and an escalation plan for red flags. Without that pathway, utilization simply relocates rather than decreasing.
8. Akili EndeavorRx (Digital Therapeutic Game For Pediatric ADHD)
EndeavorRx is frequently cited because it made the category legible to the public: a video game-like experience cleared as a treatment for pediatric ADHD. That novelty is not the point in procurement meetings; what matters is that it created a credible precedent for software-driven interventions targeting neurocognitive function. For pediatric populations, engagement is not a nice-to-have. It determines whether the treatment gets used at all.
If pediatric ADHD support is part of your benefits or clinical offering, the integration question is practical. How does EndeavorRx fit with behavioral therapy, school support plans, and medication management. Care teams often struggle to track adherence and progress between visits. A structured digital course can create observable participation data that supports follow-up conversations with families.
The other 2026 reality is that pediatric digital tools need strong guardian workflows. Consent, device access, time limits, and progress tracking must be simple. When these workflows are clumsy, families drop out even if the child initially likes the experience. Vendor evaluation should include caregiver usability testing, not only child engagement.
9. Propeller Health (Asthma And COPD Sensors Plus Digital Management)
Propeller’s model stands out because it combines sensors attached to inhalers with a smartphone app, turning medication use into trackable data and actionable feedback. It’s positioned for asthma and COPD management, offering patient-facing prompts and clinician access through a portal or API. The appeal for clinicians and payers is the direct connection between adherence behavior and costly exacerbations.
Respiratory care is one of the more operationally mature chronic care areas for digital support because medication patterns are strong signals. Propeller’s profile highlights outcomes claims that include improved adherence, reduced rescue inhaler use, and reductions in emergency department visits and hospitalizations. Those are the metrics that matter in value-based contracts, and they’re easier to measure than many behavioral health endpoints.
Implementation success depends on logistics and data flow. Sensor distribution, replacement policies, device compatibility, and patient support determine whether the program runs smoothly or stalls after initial enrollment. On the clinical side, data must be delivered in a way that supports action without creating alert fatigue. If the platform becomes “yet another dashboard,” it loses its advantage.
10. PursueCare reSET And reSET-O (Prescription Digital Therapeutics For SUD And OUD Care Plans)
reSET and reSET-O remain important names because they represent a regulated approach to substance use disorder and opioid use disorder treatment support through digital CBT. After Pear Therapeutics’ bankruptcy, PursueCare acquired and relaunched these FDA-cleared apps, returning them to patient availability. That continuity matters when organizations are wary of vendor instability in DTx.
Substance use treatment succeeds when care is connected across modalities: medication for opioid use disorder where appropriate, therapy, recovery support, and ongoing monitoring. A digital therapeutic can add structure between visits and standardize evidence-based skill practice, which is often where traditional treatment models lose people. The value is not the app alone; it’s how tightly the app is embedded into a care plan that already includes clinical touchpoints.
When evaluating reSET and reSET-O, focus on workflows and accountability. Who monitors progress, how relapse risk signals are handled, and how the platform supports re-engagement after lapses. SUD care is not linear. Your digital component must be designed for returns, not just completions.
What Are Digital Therapeutics (DTx), And How Are They Different From Health Apps In 2026?
Digital therapeutics are software-driven interventions intended to prevent, manage, or treat a medical condition, supported by clinical evidence and designed to deliver a therapeutic effect. In 2026, the market is crowded with apps that borrow clinical language, yet only a smaller subset are regulated as prescription digital therapeutics with FDA clearance or authorization. That distinction matters for claims made in marketing, labeling requirements, and how clinical teams can responsibly recommend the product.
The practical difference shows up in how you procure and govern the product. A regulated DTx behaves more like a medical device in your risk reviews, clinical oversight, and documentation. A wellness app behaves more like a consumer product, and it should be treated that way in clinical pathways. Mixing the two creates avoidable confusion for clinicians and members, then adoption drops because no one trusts the category.
You also need to recognize where the category is heading: “DTx platforms” increasingly look like care stacks. You see software paired with coaching, devices, analytics, and payer reporting because coverage and renewal hinge on measurable outcomes. If a vendor cannot show how it measures impact and how it integrates into care delivery, it will struggle to scale outside small pilots.
Which Digital Therapeutics Platforms Are Reshaping Patient Care In 2026, And What Do They Treat?
The platforms reshaping care in 2026 fall into two buckets. One bucket is FDA-cleared or authorized prescription digital therapeutics in mental health, sleep, IBS, diabetes, ADHD, and SUD or OUD support. The other bucket is enterprise platforms that may not be prescription DTx but demonstrate repeatable ROI or utilization impact in high-cost categories like MSK and cardiometabolic care. Both categories matter because the buyer ecosystem is split between clinical governance and benefit economics.
The 10 platforms listed in this article were selected because they are consistently referenced in regulated DTx discussions, enterprise benefit procurement, or condition-specific pathways with measurable outcomes. You get coverage across the major spend and access gaps: MSK pain, diabetes and weight management, depression and anxiety treatment support, insomnia therapy, respiratory disease adherence, IBS symptom reduction, pediatric ADHD, and addiction care augmentation.
If vendor selection is on the table, resist the urge to buy one platform per condition without a plan for identity, data, and member experience. The more logins you create, the more drop-off you generate. Favor platforms that support clean integration, predictable reporting, and clear member communications over platforms that only win demos.
Are Any Of These FDA-Cleared, And Which Conditions Have The Strongest Regulated DTx Options?
Several of the platforms and products listed have FDA clearance or authorization as prescription digital therapeutics or regulated medical devices. Mental health and sleep show strong regulated activity, including prescription digital CBT options for anxiety, depression symptom support, and insomnia treatment. IBS and type 2 diabetes also have notable prescription DTx options, and pediatric ADHD has a well-known cleared digital therapeutic product.
Regulated status matters because it forces labeling discipline, evidence standards, and clear statements about intended use. It also influences reimbursement pathways and prescribing workflows. If you need something that functions like a clinical treatment, prioritize the regulated set and design a workflow that supports prescribing, onboarding, and measurement. If you need broad population engagement with clear cost outcomes, evaluate enterprise platforms that can support benefit-scale deployment and claims-based reporting.
A regulatory study identified 13 FDA-cleared prescription digital therapeutics as of May 2025, illustrating how small the true prescription DTx subset still is compared with the larger health app market. That reality should shape your communications: members and clinicians must understand when they’re using a regulated treatment versus a general support tool.
Do Digital Therapeutics Improve Outcomes Or Lower Costs, And What Evidence Gets Cited In 2026?
Decision-makers typically accept two evidence types in 2026: clinical outcome improvement and measurable utilization or cost impact. Clinical outcomes include markers like A1C, symptom scales, and validated measures of function or control. Cost impact is often communicated through claims-based analyses, utilization reductions, and employer or payer ROI summaries. The buying committee will ask you to connect these to your population, not to a generic benchmark.
On the cardiometabolic side, Omada’s published reporting emphasizes long-term A1C reduction and weight maintenance across a 12-month period for members with type 2 diabetes, including baseline segmentation. On the MSK side, Hinge Health promotes ROI-oriented claims analyses, including Medicare-focused messaging and separate employer ROI claims. You should still pressure-test methodology, attribution, and inclusion criteria before building a forecast.
In mental health, regulated products like DaylightRx and Rejoyn gain credibility by aligning their claims with controlled study designs used in clearance submissions and by clearly stating intended use. Even then, outcomes at scale depend heavily on workflow and engagement. The strongest clinical evidence won’t save a program that members cannot access easily or that clinicians don’t know how to prescribe and follow.
Will Insurance Or Employers Cover Digital Therapeutics, And What Patient Complaints Show Up Most?
Coverage patterns remain uneven, with employer sponsorship and health plan contracting still dominating access for many high-volume programs. MSK and cardiometabolic platforms often expand through employer benefits because the contracting model aligns with cost avoidance goals and large-scale enrollment. Prescription digital therapeutics add another access step because they require prescribing workflows and coverage decisions that vary by payer.
Patient complaints tend to cluster around trust and friction, not around whether the clinical concept makes sense. Community discussions include billing confusion, dissatisfaction with how quickly claims appear after enrollment, and frustration around what happens when eligibility ends. These issues damage engagement quickly, and low engagement undermines outcomes, which then undermines renewals. You should treat member-facing transparency as a core product requirement, not a marketing nice-to-have.
If a platform is deployed as a benefit, insist on clear disclosures: when billing can occur, what counts as program participation, how to opt out, and what happens to devices or features when coverage ends. If the vendor cannot provide a clean explanation that a benefits team can repeat, escalation volume will rise and retention will fall.
How Do You Choose A Digital Therapeutics Platform For A Specific Condition?
Start by deciding whether you are buying a regulated treatment or a support program. If you need a regulated treatment, prioritize FDA-cleared or authorized prescription digital therapeutics and confirm that prescribing workflows and eligibility checks can run without friction. If you need population-scale utilization reduction, prioritize vendors with claims-based evidence, operational readiness, and reporting that matches your payer or employer requirements. Mixing these objectives in one pilot produces confusing success criteria and weak outcomes.
Then interrogate evidence quality and applicability. Ask whether outcomes are peer-reviewed, what populations were studied, how long results persist, and what dropout looks like. Validate that the vendor can reproduce the reporting using your data feeds and your definitions. A polished outcomes deck that cannot be mapped into your measurement stack is not useful in renewals or audits. Evaluation models described in digital therapeutics outcomes literature emphasize reproducible study design, population alignment, and real-world implementation metrics as prerequisites for scalable adoption.
Finish by stress-testing the member experience. Evaluate onboarding time, identity management, device logistics when applicable, support coverage, and offboarding rules. Run a member-journey review with benefits, clinical, compliance, and customer support stakeholders in the room. If the experience creates confusion for internal teams, it will create confusion for members at scale.
What Are The Best Digital Therapeutics Platforms In 2026?
- Hinge Health (MSK)
- Omada Health (cardiometabolic)
- Big Health DaylightRx (Rx DTx for GAD)
- Nox Health Somryst (Rx DTx for chronic insomnia)
- Click Therapeutics + Otsuka Rejoyn (Rx DTx for MDD symptoms adjunct)
- Better Therapeutics AspyreRx (Rx DTx for type 2 diabetes)
- Mahana Therapeutics Parallel/Mahana IBS (Rx DTx for IBS)
- Akili EndeavorRx (pediatric ADHD)
- Propeller Health (asthma/COPD management)
- PursueCare reSET and reSET-O (Rx DTx for SUD/OUD support)
Make Your 2026 DTx Portfolio Easier To Defend
Digital therapeutics win in 2026 when you buy with precision: match the product type to the clinical and financial objective, lock down workflows, and measure outcomes with definitions your organization already trusts. The 10 platforms covered here matter because they map to high-cost, high-volume conditions and because their market traction is supported by either regulatory positioning, measurable outcomes reporting, or both. Before contracting, pressure-test member communications, offboarding rules, and data reporting, since trust and friction decide real-world retention. When you manage DTx as a product portfolio rather than a set of pilots, you get fewer logins, cleaner measurement, and better renewals.
References
- Reddit: “Hinge Health is a scam” community thread
- PMC: Decoding FDA Labeling of Prescription Digital Therapeutics (cross-sectional regulatory study)
- Hinge Health: Employer ROI claims analysis press release
- Big Health: FDA clearance announcement for DaylightRx
- Nox Health: Acquisition announcement for Somryst
- Otsuka: FDA clearance announcement for Rejoyn
- Omada Health: Research summary on long-term A1C reduction and weight maintenance
- Digital Therapeutics Alliance: Propeller product profile
- PursueCare: reSET and reSET-O relaunch overview
- Wikipedia: EndeavorRx overview
Maurizio Chiriva Internati (DBSc, PhDs) is a cancer immunologist and biotech entrepreneur with 20+ years in immuno-oncology. Co-founder and former CEO of Kiromic BioPharma (NASDAQ: KRBP), he has led AI-driven target discovery and translational programs, and has served on faculty at MD Anderson and Texas Tech.
